CAC
JSPRW icon

Cowen and Company’s Japer Therapeutics Warrants JSPRW Stock Holding History

Cowen and Company’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,206,248
Closed -$441K – 166
2024
Q3 		$441K Buy
2,206,248
+35,499
+2% +$7.48K 0.01% 185
2024
Q2 		$434K Buy
2,170,749
+72,125
+3% +$13.1K 0.01% 185
2024
Q1 		$382K Buy
2,098,624
+248,828
+13% +$39.6K 0.01% 202
2023
Q4 		$148K Buy
1,849,796
+979,440
+113% +$81.3K 0.01% 228
2023
Q3 		$43.5K Buy
870,356
+88,015
+11% +$7.56K ﹤0.01% 303
2023
Q2 		$110K Buy
782,341
+121,325
+18% +$18.7K 0.01% 239
2023
Q1 		$132K Buy
661,016
+628,426
+1,928% +$91.8K 0.02% 173
2022
Q4 		$977 Hold
32,590
– – ﹤0.01% 622
2022
Q3 		$2K Hold
32,590
– – ﹤0.01% 580
2022
Q2 		$3K Buy
+32,590
New +$6.33K ﹤0.01% 603
2021
Q4 		– Sell
-10,200
Closed -$15K – 713
2021
Q3 		$15K Sell
10,200
-19,800
-66% -$21.2K ﹤0.01% 499
2021
Q2 		$35K Buy
+30,000
New +$28.4K ﹤0.01% 437
2021
Q1 		– Sell
-15,000
Closed -$22K – 588
2020
Q4 		$22K Hold
15,000
– – ﹤0.01% 317
2020
Q3 		$18K Hold
15,000
– – ﹤0.01% 359
2020
Q2 		$15K Sell
15,000
-59,103
-80% -$36.8K ﹤0.01% 348
2020
Q1 		$48K Buy
+74,103
New +$58.2K 0.01% 284

Other funds holding JSPRW

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cowen and Company's JSPRW Position: Q4 2024 in Review

Cowen and Company sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2024, closing a stake of 2,206,248 shares — an estimated $441K sold.

Cowen and Company first reported a position in JSPRW in Q1 2020 and held it in 16 quarters. The position peaked at $441K in Q3 2024. 5 funds tracked by Wall St. Rank hold JSPRW as of Q4 2024.

  • Cowen and Company reported no remaining Japer Therapeutics Warrants position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 2,206,248 Japer Therapeutics Warrants shares in Q4 2024, an estimated $441K.
  • Cowen and Company first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 16 quarters.
  • Cowen and Company's Japer Therapeutics Warrants position peaked at $441K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.